Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.77 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.77 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | THPO | P40225 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639751 | 1.00 | PTGS1 (0.77) | PTGS1SLC6A2ADRB2ADRB1CYP2D6 | |
| Prenalterol SCHEMBL10816429 | 0.87 | PTGS1 (1.00) | PTGS1SLC6A2ADRB2ADRB1CYP2D6 | |
| Prenalterol SCHEMBL10788435 | 0.87 | PTGS1 (1.00) | PTGS1SLC6A2ADRB2ADRB1CYP2D6 | |
| Prenalterol SCHEMBL249753 | 0.87 | PTGS1 (1.00) | PTGS1SLC6A2ADRB2ADRB1CYP2D6 | |
| SCHEMBL22640163 | 0.86 | POLB (0.59) | PTGS1SLC6A2ADRB2ADRB1CYP2D6 | |
| SCHEMBL22639709 | 0.86 | POLB (0.59) | PTGS1SLC6A2ADRB2ADRB1CYP2D6 | |
| Prenalterol SCHEMBL121857 | 0.85 | PTGS1 (0.97) | PTGS1SLC6A2ADRB2ADRB1CYP2D6 | |
| SCHEMBL5390387 | 0.85 | PTGS1 (0.74) | PTGS1SLC6A2ADRB2ADRB1CYP2D6 | |
| SCHEMBL9008475 | 0.85 | PTGS1 (0.74) | PTGS1SLC6A2ADRB2ADRB1CYP2D6 | |
| SCHEMBL7953135 | 0.85 | PTGS1 (0.74) | PTGS1SLC6A2ADRB2ADRB1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| EP-0094498-A2 | Antiatherosclerotic 1-piperazine derivatives | AMERICAN CYANAMID COMPANY (US) | 1983-11-23 | — | — | EP | claimed |
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | Exciva GmbH (DE) | 2022-10-25 | — | — | US | disclosed |
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-11-10 | — | — | US | disclosed |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | disclosed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | disclosed |
| US-6239313-B1 | FROM AN INCLUSION COMPLEX OF EPOXIDE WITH CYCLODEXTRIN AND NUCLEOPHILIC COMPOUND | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2001-05-29 | — | — | US | disclosed |
| EP-0552379-B1 | DIHYDROPYRIDINE DERIVATIVES, AND PROCESS FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-10-30 | — | — | EP | disclosed |
| EP-0086403-A2 | 2-Oxazolidine-ones | MERCK PATENT GmbH (DE) | 1983-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | HTR2A, HTR2C, CYP3A43 | PTGS1 1568/4885SLC6A2 42/4885ADRB2 61/4885 |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | PTGS1 1568/4885SLC6A2 42/4885ADRB2 61/4885 |
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | VIM, MATR3, TP53 | PTGS1 758/4885SLC6A2 2019/4885ADRB2 4055/4885 |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | PTGS1 1519/4885SLC6A2 39/4885ADRB2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.